FTC Warns Pharma Companies It Means Business with Its Orange ...

The anomaly are 19 patents asserted in 209 cases, with the majority of these being directed to Ozembic, Saxenda, and Victoza. Whether this ...

FTC warns pharma companies it means business with its Orange ...

The FTC's allegations that some patents in the FDA's Orange Book were improperly listed because they were neither new drugs nor methods of using them.

FTC Issues Policy Statement on Brand Pharmaceutical ...

The FDA's Orange Book is a list of drug products approved by the agency as safe and effective. When a brand pharmaceutical company lists a ...

IP Law News on X: "FTC warns pharma companies it means ...

FTC warns pharma companies it means business with its Orange Book listing policy https://t.co/VS4xtEXMMz | by @MBHB.

FTC Expands Patent Listing Challenges, Targeting More Than 300 ...

... Trade Commission expanded its campaign against pharmaceutical ... “It is the responsibility of branded drug manufacturers to ensure that Orange ...

Increased Scrutiny by Federal Trade Commission of Orange Book ...

The FTC has sent warning letters to several pharmaceutical companies, urging them to delist improper patents. Some companies have complied, while others argue ...

The FTC Strikes Again – Challenging the Listing of 300+ Patents in ...

On April 30, 2024, the FTC issued a press release and warning letters to ten pharmaceutical companies notifying them that the FTC had ...

The FTC Strikes Out: Drug Manufacturers Refuse to Play Ball and ...

Over the past eight months, the FTC sent two rounds of warning letters to manufacturers stating the agency's position that certain patents ...

US FTC Continues Aggressive Scrutiny of Pharmaceutical Patents ...

On April 30, 2024, the US Federal Trade Commission (“FTC”) announced that it had sent “warning letters” to 10 branded pharmaceutical ...

FTC continues to scrutinize Orange Book patent listings - DLA Piper

The Federal Trade Commission (FTC) sent its second set of warning ... the NDA is listed in the Orange Book with the drug. By listing ...

The FTC's Criticism of “Junk” Orange Book Filings - Ropes & Gray LLP

In light of the heightened regulatory scrutiny surrounding drug pricing, branded drug manufacturers should expect, and prepare for, a ...

FTC Challenges More Than 100 Patents as Improperly Listed in the ...

The Orange Book is a list of drug products approved by the FDA as safe and effective. When a brand pharmaceutical company lists a patent in the ...

Three Drug Pricing Litigation Issues to Watch in the Second Half of ...

Less than two months after the policy statement was issued, on November 7, 2023, the FTC made headlines when it sent warning letters to 10 ...

FTC Policy Statement on Orange Book Listings Brings More Clarity ...

Deputy Director Rao suggested that the FTC will be more likely to take action against a company if there are “hot doc[ument]s showing ...

Federal Trade Commission Warns Against Improper Orange Book ...

As announced in a September 14, 2023, press release, the FTC has issued a policy statement “warning pharmaceutical companies that make and ...

Fanning the Flames: FTC Takes Action Against Alleged Improper ...

In October, the FTC issued a policy statement (supported by the FDA) in which it warned brand pharmaceutical companies that they could face ...

Expansion to FTC's Orange Book Campaign Leads to Calls for More ...

While the FTC claims that such action is necessary to improve Americans' access to affordable prescription drugs, pharmaceutical industry ...

FTC warns drugmakers over improper patent filings - STAT News

In explaining its new policy statement, the FTC noted that some drug companies have failed to follow requirements for listing patents in the so- ...

Warren, Jayapal Blast Big Pharma's Sham Patent Claims, Urge ...

The letter follows the FTC's warning to the 8 drug manufacturers that they have improperly listed drug patents in the FDA's Orange Book ...

FTC challenges around 100 FDA Orange Book patent listings

The US Federal Trade Commission (FTC) announced that it issued warning letters to 10 drug manufacturers and challenged the Orange Book listings for around 100 ...